MedImpact wins summary judgment in trade secret case over misuse of its pharmacy benefit management technology
Client(s) MedImpact Healthcare Systems, Inc.
Jones Day successfully represented MedImpact Healthcare Systems, Inc. in this international trade secret litigation against IQVIA arising out of a joint venture relationship. MedImpact asserted that IQVIA misappropriated MedImpact's trade secrets in making a competing software product for pharmacy benefit management (PBM) technology. MedImpact claimed that IQVIA schemed to misappropriate MedImpact's trade secret PBM technology to create a product that competed with the parties' joint venture in the Middle East. IQVIA contested personal jurisdiction, arguing that all of the events at issue took place in the UAE. In a precedential ruling, MedImpact overcame the pleadings challenges through allegations that the defendants' virtual presence in California met the minimum contacts standard for personal jurisdiction. Jones Day steered the case through two years of international discovery and successful outcomes in multiple rounds of jurisdictional fights, summary judgment motions and Daubert challenges. Importantly, MedImpact won summary judgment that its trade secrets are protectable and that IQVIA's accused product uses MedImpact's misappropriated trade secrets.
MedImpact Healthcare Systems, Inc. et al. v. IQVIA Holdings Inc. et al., Nos. 3-19-cv-01865 (S.D. Cal.)